|
000
| 02314nam 2200409zi 4500 |
|---|
| 001 | 9.934198 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240510083143 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 240220e202403 oncd ob f000 0 eng d |
|---|
| 020 | |a9780660703886|q(report) |
|---|
| 020 | |a9780660703893|q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-239/1-2024E-PDF |
|---|
| 086 | 1 |aHP5-239/2-2024E-PDF |
|---|
| 245 | 00|aRecommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMarch 2024. |
|---|
| 264 | 4|c©2024 |
|---|
| 300 | |a1 online resource (65 pages) : |bcolour charts + |e1 summary (4 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aIssued also in French under title: Recommandations pour les programmes de santé publique sur l'utilisation des vaccins contre le pneumocoque chez les enfants, y compris l'utilisation des vaccins conjugués 15-valent et 20-valent. |
|---|
| 500 | |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 230765 (report). Pub.: 230767 (summary)”. |
|---|
| 504 | |aIncludes bibliographical references (pages 46-49). |
|---|
| 650 | 0|aVaccination of children|xGovernment policy|zCanada. |
|---|
| 650 | 0|aPneumococcal vaccine|xGovernment policy|zCanada. |
|---|
| 650 | 0|aStreptococcus pneumoniae|xVaccination|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRecommandations pour les programmes de santé publique sur l'utilisation des vaccins contre le pneumocoque chez les enfants, y compris l'utilisation des vaccins conjugués 15-valent et 20-valent.|w(CaOODSP)9.934199 |
|---|
| 856 | 40|qPDF|s1.58 MB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP5-239-1-2024-eng.pdf|zReport |
|---|
| 856 | 40|qPDF|s373 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP5-239-2-2024-eng.pdf|zSummary |
|---|